TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
News|Slideshows|November 23, 2021
Obesity Stigma in Clinical Practice: Ask Yourself these 8 Questions
Author(s)Leo Robert
Weight bias themes in primary care are the subject of contemporary research. Which options you choose to these 8 questions may offer insight into your own unconscious prejudices.
Advertisement
Health care professionals, like persons in all walks of life, may hold strong negative attitudes and stereotypes about individuals with obesity. These negative attitudes, whether conscious or not, can have a negative impact on clinical encounters, quality of care, and patient outcomes.
This quick quiz is based on current research into weight bias among health care providers, and particularly those in primary care. The answers you choose may give you insight into your own personal prejudices.
Advertisement
Related to this article
EASD 2026: Oral semaglutide users lost 4.1% of body weight 3 months after switching from injections in an observational study without a comparator group.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
JoAnn Pinkerton, MD, discusses new research she presented at The Menopause Society 2026 Annual Meeting on elinzanetant for menopausal vasomotor symptoms.
TMS 2026: Women exercising at least 5 days a week reported lower perimenopause symptom scores across psychological, somatic, and urogenital domains.
Advertisement
Advertisement
Trending on Patient Care Online
1
Menopause Diagnoses Documented in Just 7.8% of Midlife Women's Outpatient Visits, Study Finds
2
JoAnn Pinkerton, MD, on Counseling Patients Starting Elinzanetant for VMS
3
Menopause Hormone Therapy Linked to Greater Weight Loss With Semaglutide in Real-World Study
4
Fezolinetant May Improve Depression, Anxiety Symptoms in Women With Menopausal VMS
5